Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia

Xavier Thomas
2014 Blood and Lymphatic Cancer : Targets and Therapy  
Monoclonal antibodies are likely to make a considerable contribution in the treatment of acute lymphoblastic leukemia (ALL). High expression of CD22 antigen is found on the surface of leukemia cells in ALL. Inotuzumab ozogamicin, a CD22 monoclonal antibody conjugated to calicheamicin, which has shown efficacy in patients with lymphomas, has also shown encouraging activity in relapsed or refractory ALL with a high morphologic and molecular response rate. This article summarizes the current
more » ... s the current approaches to treating ALL with inotuzumab ozogamicin, based on available data from the literature.
doi:10.2147/blctt.s49048 fatcat:v4x5ikcenrgh5fohz57wksv36i